

April 24, 2024

Index	Up/Down	(%)	Points	Index Closing
S&P BSE SENSEX	↑	0.16	114.49	73,852.94
NIFTY 50	↑	0.15	34.40	22,402.40
S&P BSE MIDCAP	↑	0.92	372.53	40,956.70
S&P BSE SMALLCAP	↑	0.79	366.39	46,858.60
S&P BSE 500	↑	0.39	126.77	32,716.27

Index	Open	High	Low	Close	52 W High	52 W Low
SENSEX	73,957.57	74,121.61	73,788.61	73,852.94	75,124.28	59,954.91
NIFTY	22,421.55	22,476.45	22,384.00	22,402.40	22,775.70	17,885.30

SENSEX Gainers	17	NIFTY Gainers	28	Sectors Posted Gain	19
SENSEX Losers	13	NIFTY Losers	22	Sectors Posted Loss	3
Advances Declines Advance/Decline Ratio Unchanged					
BSE	2228	1594	11:8	107	
NSE	1564	984	5:3	90	

Top 5 SENSEX Drivers				Top 5 Gainers & Losers (X – Sensex)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
JSW Steel	3.7	Tech Mahindra	-1.2	Forbes Gokak	20.0	Umiya Tubes	-11.4
Tata Steel	2.7	TCS	-1.1	Raj Oil Mills	20.0	S V J Enterprise	-10.0
Power Grid Corp	2.7	Maruti Suzuki	-0.7	Objectone Info	20.0	Golkonda Alum	-9.9
Kotak Mahindra	1.7	Infosys	-0.7	Active Clothing	20.0	Atal	-9.9
UltraTech Cement	1.6	Reliance	-0.6	Megri Soft	20.0	Quantum Build	-9.5

Top 5 NIFTY Drivers				Top 5 Gainers & Losers (X – NIFTY)			
Gainers	(%)	Losers	(%)	Gainers	(%)	Losers	(%)
Hindalco	3.9	Tata Cons Products	-5.4	Tac Infosec	20.0	Atal	-9.7
Cipla	3.8	Grasim	-1.4	Raj Oil Mills	20.0	Vodafone Idea	-9.0
JSW Steel	3.7	Tech Mahindra	-1.2	Compucom Soft	19.9	Huhtamaki India	-8.2
Tata Steel	2.7	HDFC Life	-1.2	Shradha Infra	19.8	S H Kelkar	-7.6
Power Grid Corp	2.7	TCS	-1.1	Steel City Secu	19.8	Smart Link Net	-7.2

FII/FPI/DII trading activity across Indian Exchanges – CM (Rs. In Cr.)				
Category	Date	Buy Value	Sell Value	Net Value
FII/FPI	24-Apr-2024	10,242.95	12,754.69	-2,511.74
DII	24-Apr-2024	12,601.22	8,791.32	3,809.90



Sectorial Contribution in SENSEX							
Index	(%)	Index	(%)	Index	(%)	Index	(%)
Metal	2.8	Capital Goods	0.9	Bankex	0.5	FMCG	0.1
Commodities	1.6	Infrastructure	0.8	Utilities	0.5	Auto	0.1
PSU	1.2	Realty	0.8	Consumer Durables	0.5	Telecom	-1.4
Industrials	1.1	Services	0.8	Financial Services	0.4	TECK	-0.8
Healthcare	1.0	Energy	0.7	Manufacturing	0.3	IT	-0.6
Oil & Gas	1.0	Power	0.5	Consumer Discretionary	0.2		

Chennai Petroleum stock up 18.3% on strong Q4 results, dividend announcement:

Chennai Petroleum Corporation stock price soared 18.3% to Rs 1,098, also its fresh record high, in today's intraday trade after the energy firm posted solid January-March quarter result (Q4FY24). That apart, the company's 100% rise in dividend payout further boosted investor sentiment. On Wednesday, April 24, 2024, Chennai Petroleum reported a whopping 71% Q-o-Q rise in consolidated net profit at Rs 627.89 crore vs PAT of Rs 365.3 crore posted in the December quarter. On a yearly basis, the profit was down from Rs 1,012.8 crore. Revenue from operations came in at Rs 20,822.95 crore as against Rs 20,453.94-crore revenue reported in Q3FY24, and Rs 21,350.05 crore in Q4FY23. EBITDA of the quarter grew 53.2% Q-o-Q to Rs 1,042 crore, while margin expanded to 5.88% from 3.91% in December. On the dividend front, the Indian Oil Corporation-subsiary said that it will pay a final dividend of Rs 55 per share for FY24. "The board of directors of the company has recommended an equity dividend (final) of 550% for financial year 2023-2024 i.e, Rs 55 per equity share of a face value Rs 10 each on the paid-up share capital, subject to the approval of shareholders at the ensuing annual general meeting of the company," the company said in an exchange filing.

Zydus Life stock shed 4.7% as USFDA issues 10 observations for Vadodara unit:

Shares of Zydus Lifesciences shed 4.7% to hit an intraday low of Rs 916.4 per share after the US Food and Drug Administration (USFDA) issued 10 observations against the company's Injectable Manufacturing site in Vadodara. "The USFDA conducted an inspection at the Injectable Manufacturing site situated at Jarod, near Vadodara, between April 15 and April 23, 2024. The inspection was closed with 10 observations," the company said in an exchange filing. Going ahead, the company will closely work with the USFDA to address and respond to the observations in an expeditious manner, it added. Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), is one of India's leading pharmaceutical companies. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus provides comprehensive and complete healthcare solutions.

Puravankara locked at 5% upper circuit on securing redevelopment project:

Real estate company Puravankara shares were locked in 5% upper circuit on Wednesday. The shares hit an intraday high of Rs 377 per share. The surge came after Puravankara announced that it has been selected as the preferred developer for redeveloping a residential housing society in Mumbai's Pali Hill. In an exchange filing, Puravankara said, "We write to inform you that the company has been unanimously selected as the preferred developer for redeveloping a residential housing society in Pali Hill, Mumbai." The project has a cumulative estimated development potential of 4.10 lakh sq ft carpet area, with approximately 2.15 lakh sq ft available for sale, and a potential Gross Development Value (GDV) of over Rs 2,000 crore, the company said in a statement. Puravankara claimed that the residential society is spread slightly over two and a half acres and is one of the largest in the micro-market.

Welspun Corp shares gained 4.3% on winning Rs 611-crore order:

Shares of Welspun Corp advanced over 4.3% to Rs 586 today after the company announced that it's won a Rs 611-crore letter of award for export of line pipes. The order consists of LSAW (longitudinal double submerge arc welding) pipes from Latin America. The company will execute the contract in FY25, Welspun said in a regulatory filing. This is the second such order in quick succession. On April 22, the company announced that it had secured orders totalling Rs 872 crore within the last month to provide multiple-line pipes, with projects spanning both India and the US. These orders are also slated for execution in FY25. According to the company's stock exchange filing, it obtained these orders valued at Rs 872 crore since the last disclosure made on March 22. One of these orders entails supplying coated LSAW pipes and bends for a significant oil transportation initiative in the Middle East, specifically designed for extremely sour service application.



Index	CMP @ 07.22 pm	Points Up/Down	(%) Up/Down
Gold	2,329.90	-11.95	-0.51
Silver	27.170	-0.197	-0.72
Brent Crude	87.97	-0.43	-0.49
WTI Nymex Crude	82.75	-0.59	-0.71
Natural Gas	2.026	-0.064	-3.06

Index	CMP @ 07.19 pm	Points Up/Down	(%) Up/Down
Asia Pacific			
Shanghai Composite	3,044.82	22.84	0.75
GIFT NIFTY	22,400.00	-20.00	-0.09
Nikkei 225	38,460.08	907.92	2.36
Hang Seng	17,201.27	372.34	2.16
Europe			
FTSE 100	8,067.25	22.44	0.28
DAX	18,130.87	-6.78	-0.04
CAC	8,122.13	16.35	0.20
America			
Dow Jones	38,462.78	-40.91	-0.11
S&P 500	5,083.84	13.29	0.26
Nasdaq Composite	15,825.44	128.80	0.82

**Disclosures and Disclaimer**

Disclosures and Disclaimers: This Report is published by Sunidhi Securities & Finance Limited (hereinafter referred to as "Sunidhi") SEBI Research Analyst Registration Number: INH000001329 for private circulation. Sunidhi is a registered Stock Broker with National Stock Exchange of India Limited, BSE Limited and Metropolitan Stock Exchange of India Limited in cash, derivatives and currency derivatives segments. It is also having registration as a Depository Participant with CDSL.

Sunidhi has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

Sunidhi or its associates has not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. Sunidhi or analyst or his relatives do not hold any financial interest in the subject company. Associates may have such interest in its ordinary course of business as a distinct and independent body. Sunidhi or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the company covered by Analyst.

Sunidhi or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. Sunidhi or its associates has not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of subject company and Sunidhi / analyst has not been engaged in market making activity of the subject company.

Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. Sunidhi or its associates may have investment positions in the stocks recommended in this report, which may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. However, Sunidhi is maintaining Chinese wall between other business divisions or activities. Analyst has exercised due diligence in checking correctness of details and opinion expressed herein is unbiased.

This report is meant for personal informational purposes and is not be construed as a solicitation or financial advice or an offer to buy or sell any securities or related financial instruments. While utmost care has been taken in preparing this report, we claim no responsibility for its accuracy. Recipients should not regard the report as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without any notice and this report is not under any obligation to update or keep current the information contained herein. Past performance is not necessarily indicative of future results. This report accepts no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this report.

Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Sunidhi or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Sunidhi has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Sunidhi endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Neither Sunidhi nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

Sunidhi Securities & Finance Ltd. – Research Analyst – INH000001329

Kalpataru Inspire, Unit.1, 8th floor, Opp. Grand Hyatt Hotel, Santacruz East, Mumbai-400055

Bombay Stock Exchange (BSE)	National Stock Exchange of India Ltd (NSE)	Metropolitan Stock Exchange of India Limited (MSEI)
Registration no. INZ000169235	Registration no. INZ000169235	Registration no. INZ000169235
Compliance Officer Name:	Mr. Mahesh Desai	Phone No: 9122-66771777